These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Observation on effect of chongcao shenkang capsules in preventing and treating acute renal failure in cases of hemorrhagic fever with renal syndrome].
    Author: Fu C, Song S, Shi Y.
    Journal: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun 30; 13(2):188-90. PubMed ID: 12569793.
    Abstract:
    OBJECTIVE: To observe the effect of Chongcao shenkang capsules in preventing and treating acute renal failure in cases of hemorrhagic fever with renal syndrome (HFRS). METHODS: 150 cases of HFRS were randomly divided into two groups: the treatment group and the control group. The former contained 76 cases and the latter the 74 cases. All cases in both groups were given a combined therapy mainly composed of balanced salt solution and ribavirin, cases in treatment group additionally accepted Chongcao shenkang capsules 2.7 grams tid, till the end of polyuric phase. RESULTS: The results showed that in the treatment group the occurrence rate of cases with oliguric phase was 13.0% (4/46) and the oliguric and polyuric periods were 2.7 +/- 1.6 days and 6.8 +/- 2.9 days respectively while those in the control group were 31.1% (4/45), 4.3 +/- 2.1 dnys and 8.2 +/- 3.4 days respectively (P < 0.01 or P < 0.05). The urinary protein of the treatment group disappeared within 5.1 +/- 2.3 days and their serum creatinine restored within 10.9 +/- 6.2 days, but the urinary protein disappearing and the serum creatinine restoring periods of the control group were 6.8 +/- 2.7 days and 13.7 +/- 7.4 days respectively (P < 0.01 or P < 0.05). The serum and urine beta 2-microglobulin levels of the treatment group were remarkably lower than those of the control group on the fifth and tenth days after treatment (P < 0.01 or P < 0.05). Compared with those of the control group of 33.8% (25/74) and 87.8% (65/74), the occurrence rate of severe complications and curative rate of the treatment group were 18.4% (14/76) and 94.7% (72/76) respectively (the former P < 0.05, but the latter P > 0.05). CONCLUSION: It was concluded that Chongcao shenkang capsules is capable of reducing the occurrence rate of acute renal failure in HFRS patients, shortening the duration of acute renal failure, decreasing their needs for dialysis, lessening their complications and increasing their curative rate. Its administration is safe and convenient and therefore it is worthy to be popularized.
    [Abstract] [Full Text] [Related] [New Search]